Tomoki Yaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomoki Yaguchi has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Kiwako Yamamoto-Hanada
Allergy Center, National Center for Child Health and Development, Tokyo, Japan
10 shared publications - Tatsuki Fukuie
Allergy Center, National Center for Child Health and Development
10 shared publications - Kenji Toyokuni
Allergy Center National Center for Child Health and Development Tokyo Japan
9 shared publications - Yukihiro Ohya
Department of Occupational and Environmental Health Nagoya City University Nagoya Japan
8 shared publications - Daisuke Harama
Allergy Center National Center for Child Health and Development Tokyo Japan
6 shared publications - Kotaro Umezawa
Allergy Center National Center for Child Health and Development Tokyo Japan
6 shared publications
Latest Publications
- 26 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Storage‐Associated Reduction in ELISA‐Detectable Walnut Allergen Levels Does Not Reflect Functional Allergenicity
Summary: Commercial ELISA measurements declined during walnut powder storage, while total protein concentrations remained broadly stable. Patient serum IgE binding and basophil activation showed no consistent decline corresponding to ELISA measurements.
- 26 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Storage‐Associated Reduction in ELISA‐Detectable Walnut Allergen Levels Does Not Reflect Functional Allergenicity
Summary: Commercial ELISA measurements declined during walnut powder storage, while total protein concentrations remained broadly stable. Patient serum IgE binding and basophil activation showed no consistent decline corresponding to ELISA measurements.
- 14 July 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (9) , 1381-1384
Restraint‐Free Initiation of Dupilumab in a Child With Autism Spectrum Disorder: Overcoming Procedural Barriers in Atopic Dermatitis
Children with autism spectrum disorder (ASD) often experience significant distress during medical procedures, which can limit access to optimal treatments such as biologic therapy for atopic dermatitis (AD). However, practical strategies for initiating injectable biologic therapy without physical restraint in this population remain poorly described. We report a case demonstrating a structured and reproducible approach that enabled restraint‐free initiation of dupilumab in a child with ASD. A 6‐year‐old boy with moderate‐to‐severe AD and comorbid ASD had a history of severe procedural avoidance requiring physical restraint for blood sampling and vaccinations. He was admitted for remission induction and consideration of dupilumab therapy. A Certified Child Life Specialist conducted an individualized intervention beginning early in hospitalization, including assessment of sensory sensitivities, visual preparation, environmental modification, and procedural rehearsal. On hospital Day 11, the first subcutaneous injection of dupilumab was successfully administered without physical restraint or additional staff assistance. A coordinated multidisciplinary strategy was implemented, including minimized sensory stimulation, predefined team roles, and distraction techniques. No adverse events occurred, and subsequent injections were performed smoothly in the outpatient setting without further specialized support. This case provides a practical and reproducible framework for overcoming procedural barriers and safely initiating biologic therapy in children with ASD.
- 14 July 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (9) , 1381-1384
Restraint‐Free Initiation of Dupilumab in a Child With Autism Spectrum Disorder: Overcoming Procedural Barriers in Atopic Dermatitis
Children with autism spectrum disorder (ASD) often experience significant distress during medical procedures, which can limit access to optimal treatments such as biologic therapy for atopic dermatitis (AD). However, practical strategies for initiating injectable biologic therapy without physical restraint in this population remain poorly described. We report a case demonstrating a structured and reproducible approach that enabled restraint‐free initiation of dupilumab in a child with ASD. A 6‐year‐old boy with moderate‐to‐severe AD and comorbid ASD had a history of severe procedural avoidance requiring physical restraint for blood sampling and vaccinations. He was admitted for remission induction and consideration of dupilumab therapy. A Certified Child Life Specialist conducted an individualized intervention beginning early in hospitalization, including assessment of sensory sensitivities, visual preparation, environmental modification, and procedural rehearsal. On hospital Day 11, the first subcutaneous injection of dupilumab was successfully administered without physical restraint or additional staff assistance. A coordinated multidisciplinary strategy was implemented, including minimized sensory stimulation, predefined team roles, and distraction techniques. No adverse events occurred, and subsequent injections were performed smoothly in the outpatient setting without further specialized support. This case provides a practical and reproducible framework for overcoming procedural barriers and safely initiating biologic therapy in children with ASD.
- 19 April 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 966-968
Low‐Dose, Slow‐Escalation Home‐Based and Sustainable Oral Immunotherapy for Walnut and Cashew Allergy: A Retrospective Case Series
Summary Box: Low‐dose, slow‐escalation oral immunotherapy was well tolerated in children with walnut and cashew allergies. No anaphylaxis occurred, and many children achieved clinical tolerance for unrestricted daily walnut and cashew intake.
- 19 April 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 966-968
Low‐Dose, Slow‐Escalation Home‐Based and Sustainable Oral Immunotherapy for Walnut and Cashew Allergy: A Retrospective Case Series
Summary Box: Low‐dose, slow‐escalation oral immunotherapy was well tolerated in children with walnut and cashew allergies. No anaphylaxis occurred, and many children achieved clinical tolerance for unrestricted daily walnut and cashew intake.
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
Background: The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow‐up study (PACI‐ON) evaluated whether these effects persisted to age 3 years. Methods: Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow‐up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician‐diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results: At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between‐group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with > 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion: Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow‐up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
Background: The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow‐up study (PACI‐ON) evaluated whether these effects persisted to age 3 years. Methods: Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow‐up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician‐diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results: At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between‐group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with > 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion: Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow‐up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.
- 5 January 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (2) , 186-189
Trends in Emergency Department Visits for Food Allergy in Children Before and After Early Introduction Guidelines in Japan: A 10‐Year Retrospective Study From a National Tertiary Centre
SUMMARY: Early egg introduction guidelines have not reduced food allergy emergency visits in Japan. Tree nut allergy attendances increased, highlighting gaps in current prevention strategies.
- 5 January 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (2) , 186-189
Trends in Emergency Department Visits for Food Allergy in Children Before and After Early Introduction Guidelines in Japan: A 10‐Year Retrospective Study From a National Tertiary Centre
SUMMARY: Early egg introduction guidelines have not reduced food allergy emergency visits in Japan. Tree nut allergy attendances increased, highlighting gaps in current prevention strategies.
- Open Access
- 12 December 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (4) , 427-429
Early Walnut Powder Introduction for Prevention of Walnut Sensitisation in High‐Risk Infants With Eczema: An Open‐Label, Randomised, Non‐Inferiority Trial
Summary: Early walnut powder introduction in high‐risk infants may suppress walnut sensitisation without safety concerns. This randomised non‐inferiority trial compares introduction at 6–8 months versus 12–14 months of age.
- 12 December 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (4) , 427-429
Open AccessEarly Walnut Powder Introduction for Prevention of Walnut Sensitisation in High‐Risk Infants With Eczema: An Open‐Label, Randomised, Non‐Inferiority Trial
Summary: Early walnut powder introduction in high‐risk infants may suppress walnut sensitisation without safety concerns. This randomised non‐inferiority trial compares introduction at 6–8 months versus 12–14 months of age.
- 2 December 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (4) , 424-426
Feasibility of Early Nut Introduction Using Low‐Protein Recipes in Healthy Infants: A Single‐Arm Prospective Intervention Study (Phase One)
Summary Box: Early nut introduction using low‐protein powdered recipes is feasible for infants at home. Regular low‐dose nut intake may aid allergy prevention, pending confirmation in future trials.
- 2 December 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (4) , 424-426
Feasibility of Early Nut Introduction Using Low‐Protein Recipes in Healthy Infants: A Single‐Arm Prospective Intervention Study (Phase One)
Summary Box: Early nut introduction using low‐protein powdered recipes is feasible for infants at home. Regular low‐dose nut intake may aid allergy prevention, pending confirmation in future trials.
- 9 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (12) , 1261-1263
High Stratum Corneum Hydration May Predict Atopic Dermatitis Development in Moisturised Infants
- 9 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (12) , 1261-1263
High Stratum Corneum Hydration May Predict Atopic Dermatitis Development in Moisturised Infants
- 16 September 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (1) , 72-75
Quality of Life in Paediatric Food Allergy: Diverging Influences on Parent and Child Reports in the ROAD Study
- 16 September 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (1) , 72-75
Quality of Life in Paediatric Food Allergy: Diverging Influences on Parent and Child Reports in the ROAD Study
- 15 June 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (11) , 1134-1137
Real‐World Evaluation of Associations Between Regular Intake and Food Challenge Outcome in Children
- 15 June 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (11) , 1134-1137
Real‐World Evaluation of Associations Between Regular Intake and Food Challenge Outcome in Children